Predictors of tumor progression of low-grade glioma in adult patients within 5 years follow-up after surgery

Abstract

BackgroundGlioma originates from glial cells in the brain and is the most common primary intracranial tumor. This study intends to use a retrospective analysis to explore the factors that can predict tumor progression in adult low-grade gliomas, namely WHO II grade patients, within 5 years after surgery.MethodsPatients with WHO grade II glioma who were surgically treated in our hospital from February 2011 to May 2017 were included. According to the inclusion and exclusion criteria, 252 patients were included in the final analysis. According to the results of the 5-year follow-up (including survival and imaging review results), patients were divided into progression-free group and progression group. Univariate and multivariate analysis were conducted to investigate the related factors of tumor progression during the 5-year follow-up.ResultsThe results of the 5-year follow-up showed that 111 (44.0%) cases had no progress (progression free group, PFG), 141 (56.0%) cases had progress (progression group, PG), of which 43 (30.5%) cases were operated again, 37 cases (26.2%) received non-surgical treatments. There were 26 (10.3%) all-cause deaths, and 21 (8.3%) tumor-related deaths. Univariate and multivariate analysis showed that age >45 years old (OR = 1.35, 95% CI, 1.07–3.19, P = 0.027), partial tumor resection (OR = 1.66, 95% CI, 1.15–3.64, P = 0.031), tumor diameter >3 cm (OR = 1.52, 95% CI, 1.14–4.06, P = 0.017) and no radiotherapy (OR = 1.37, 95% CI, 1.12–2.44, P = 0.039) were independent predictors of the progression of tumor during the 5-year follow-up period.ConclusionAge >45 years old, partial tumor resection, tumor diameter >3 cm, no radiotherapy are predictors for tumor progression for glioma patients after surgery.

Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas

“…Studies have shown that patients who undergo a more than 90% extent of resection have a 5-year overall survival rate of 97%, whereas those who undergo a less than 90% extent of resection have a reduced 5-year overall survival rate of 76% [ 3 , 4 ]. With regard to disease progression, up to 56% of patients (141 cases) experienced progression in a 5-year follow-up study [ 5 ]. Isocitrate dehydrogenase (IDH) mutation status significantly impacts disease progression, as demonstrated in studies that showed IDH-mutant (IDHmut) tumors having significantly longer progression-free survival (PFS) and overall survival (OS) compared to their IDH wild-type (IDHwt) counterparts [ 6 , 7 , 8 , 9 ].…”